A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Registration Number
- NCT00157534
- Lead Sponsor
- BioWest Therapeutics Inc
- Brief Summary
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
- The patient must be 18 to 65 years of age, inclusive.
- Primary diagnosis of chronic HCV infection.
Exclusion Criteria
- Patients who did not respond or relapsed following therapy with interferon.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Safety analysis
- Secondary Outcome Measures
Name Time Method Hepatitis C viral load
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Celgosivir target in chronic Hepatitis C genotype 1 infection?
How does Celgosivir's efficacy compare to standard-of-care treatments for Hepatitis C genotype 1 in Phase II trials?
Which biomarkers correlate with response to Celgosivir in patients with chronic Hepatitis C genotype 1 infection?
What adverse events were observed in the Phase II trial NCT00157534 and how were they managed?
Are there combination therapies involving Celgosivir that show improved outcomes for Hepatitis C genotype 1 compared to monotherapy?